<DOC>
	<DOCNO>NCT00773695</DOCNO>
	<brief_summary>This 2 arm study evaluate effect Avastin , combination chemotherapy endocrine therapy , preoperative treatment patient HER2 negative breast cancer . Patients randomize receive either chemotherapy ( FEC100 4 x 3weekly cycle endocrine therapy ( aromatase inhibitor daily 24 week ) without Avastin ( 15mg/kg iv every 3 week ) .The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Neoadjuvant Treatment Regimens Patients With Primary HER2 Negative Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; HER2negative breast cancer , &gt; =2.5cm size ; ECOG/WHOperformance status &lt; =2 ; normal baseline cardiac function ( LVEF ) . stage IV ( metastatic ) disease ; previous treatment localize breast cancer &lt; 24 month diagnosis present breast cancer ; previous current cancer except basal cell cancer situ cervical cancer ; current recent use aspirin ( &gt; 325mg/day ) ; clinically significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>